©2025 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy
Art of Drug Choice Header Bar

Editorial Feature:

The Art of Drug Choice

Wet AMD and the Latest Data

Editorially Independent content supported with advertising by Novartis and Alcon.

Switching to a New Anti-VEGF Agent Early in the Course of Therapy

Seenu M. Hariprasad, MD

Show Description +

The uncertainty surrounding the early days of the COVID-19 pandemic resulted in unique treatment regimens. What happened when a patient with wet AMD switched from aflibercept (Eylea, Regeneron) to brolucizumab (Beovu, Novartis) on her third dose of anti-VEGF therapy? Seenu M. Hariprasad, MD, profiles his patient’s response to this unusual adjustment.

Posted: 8/05/2021

Keywords:

Wet AMD

•

brolucizumab

•

aflibercept

•

Anti-VEGF

Up Next

Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy
Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy

Peter Kertes, MD, FRCS(C)

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation
Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Arshad M. Khanani, MD, MA

Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient
Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient

Arshad M. Khanani, MD, MA

Switching Agents Multiple Times in a Long-term Wet AMD Patient
Switching Agents Multiple Times in a Long-term Wet AMD Patient

Lejla Vajzovic, MD

Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient
Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient

Joseph M. Coney, MD

Increasing Treatment Intervals in Wet AMD
Increasing Treatment Intervals in Wet AMD

Arshad M. Khanani, MD

A Breakthrough After Monthly Wet AMD Therapy
A Breakthrough After Monthly Wet AMD Therapy

Nikolas J.S. London, MD

Navigating Treatment Burden in Wet AMD
Navigating Treatment Burden in Wet AMD

Christina Weng, MD, MBA

Outside-the-Box Therapy for Wet AMD
Outside-the-Box Therapy for Wet AMD

Christopher G. Fuller, MD

The Value of Treatment Options in Wet AMD
The Value of Treatment Options in Wet AMD

Justus G. Garweg, MD

link-arrow   Back to All Videos

Switching to a New Anti-VEGF Agent Early in the Course of Therapy

Seenu M. Hariprasad, MD

The uncertainty surrounding the early days of the COVID-19 pandemic resulted in unique treatment regimens. What happened when a patient with wet AMD switched from aflibercept (Eylea, Regeneron) to brolucizumab (Beovu, Novartis) on her third dose of anti-VEGF therapy? Seenu M. Hariprasad, MD, profiles his patient’s response to this unusual adjustment.

Posted: 8/05/2021

Keywords:

Wet AMD

•

brolucizumab

•

aflibercept

•

Anti-VEGF

Please log in to leave a comment.

Listen as a Podcast

nrr podcast logo

New Retina Radio

All video episodes of this series are also available as podcast episodes on New Retina Radio.

Listen Now

close-x